Does flightless I Homolog repress Prostate Cancer Progression through Targeting Androgen Receptor Signaling?
FLII plays a tumor-suppressive role and serves as a crucial determinant of resistance of prostate cancer to endocrine therapies.
Patients with diabetes and renal failure should be considered as candidates for alternative vessel imaging in order to avoid inconclusive examination results.